When does lenvatinib’s patent (and exclusivity) run out?
Lenvatinib’s patent and market exclusivity timeline depends on the specific jurisdiction and the particular patent family covering different claim types (drug substance, formulations, and manufacturing/process). Patent terms also interact with regulatory exclusivity rules that can extend market protection beyond the base patent expiry.
DrugPatentWatch.com tracks these timeframes by tying patents to the branded product and filings in relevant markets, which is often the fastest way to see “latest expiry” dates researchers and generic companies monitor. You can check it here: DrugPatentWatch.com – Lenvatinib (patent and exclusivity information)
What patents are being watched for lenvatinib—drug substance or formulations?
Lenvatinib is typically protected by multiple layers of intellectual property rather than a single patent. Competitors often focus on patents that cover:
- the core drug substance (basic compound claims),
- specific crystalline forms, salts, or polymorphs,
- particular dosing forms or manufacturing processes.
Those layers can lead to staggered expiry dates, so “the lenvatinib patent” may not have one single expiration date. Patent-watch tools (including DrugPatentWatch.com) break down the relevant families so you can see which one is controlling in each country. [1]
Why do generic or biosimilar challengers care about lenvatinib patents?
Generic entrants and other challengers use lenvatinib patent data to estimate whether they can launch right after legal expiry or whether they must wait for later-expiring patents in the same family or related families.
This also affects:
- timing of abbreviated approval submissions (where applicable),
- launch “at-risk” dates if litigation is pending,
- settlement timing if parties reach agreements.
Patent listings and expiry projections are exactly the kind of information companies and litigators use when assessing a launch window. [1]
What happens if a lenvatinib patent is still active but other patents expire?
When multiple patents protect different aspects of the product, one expiry may not be enough to clear the way. A generic (or other competitor) may still face injunction risk or infringement exposure if later-expiring patents remain in force.
That’s why patent-monitoring sources map out the full set of relevant patents and pick the “latest” or “most relevant” one for launch planning. [1]
Where can I check the exact lenvatinib patent expiry dates I care about?
Use a patent-tracking page that lists individual patent numbers and projected expiry by jurisdiction, then filter to:
- the country (US, EU, UK, etc.),
- the branded product(s) the patents are tied to,
- the “earliest” vs “latest” expiry dates among the relevant families.
DrugPatentWatch.com is one such consolidated resource for lenvatinib. [1]
---
Sources cited
- DrugPatentWatch.com – Lenvatinib (patent and exclusivity information)